How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/a4250-odevixibat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

A4250 (odevixibat) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A4250 (odevixibat) (A4250 (odevixibat)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid transporter inhibitor. Area: Hepatology / Gastroenterology.

phase 3 Bile acid transporter inhibitor IBAT (ileal bile acid transporter; SLC10A2) Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

A4250 (odevixibat) (A4250 (odevixibat)) — Albireo. Odevixibat inhibits the ileal bile acid transporter (IBAT) to reduce bile acid reabsorption and increase fecal excretion, thereby lowering serum bile acids.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A4250 (odevixibat) TARGET	A4250 (odevixibat)	Albireo	phase 3	Bile acid transporter inhibitor	IBAT (ileal bile acid transporter; SLC10A2)
Bylvay	ODEVIXIBAT	Ipsen	marketed	Ileal Bile Acid Transporter Inhibitor [EPC]	Ileal sodium/bile acid cotransporter	2021-01-01
Livmarli	maralixibat hydrochloride	Mirum Pharma Inc	marketed	Ileal Bile Acid Transporter Inhibitor	Ileal sodium/bile acid cotransporter	2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-05-26 — Livmarli · 11260053 · US
2032-10-26 — Livmarli · 11376251 · US
2040-02-12 — Livmarli · 11497745 · US
2040-02-12 — Livmarli · 11229647 · US

Sponsor landscape (Bile acid transporter inhibitor class)

Albireo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A4250 (odevixibat) — Competitive Intelligence Brief. https://druglandscape.com/ci/a4250-odevixibat. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing